CELG : Analysis & Opinions

  1. Key Financial Ratios to Analyze Biotech Companies

    August 20, 2015
    Explore the rapidly growing biotechnology industry, and learn some of the key financial ratios investors use to analyze companies ...
  2. Top 3 Biotech ETFs

    August 14, 2015
    Learn about three popular ETFs in the biotechnology sector, how they differ, and which ones may be appropriate for long term ...
  3. Celgene Vs. Gilead: Vetting for the Best Biopharma

    August 14, 2015
    Read about the similarities between the drug companies Celgene and Gilead, and learn about promising potential drug candidates ...
  4. Avoid The Perfection Trap In Trading

    August 12, 2015
    Avoid the perfection trap and make peace with the market’s high levels of systematic noise.
  5. ETF Analysis: iShares NASDAQ Biotechnology

    August 7, 2015
    Learn about the iShares Nasdaq Biotechnology exchange-traded fund, which offers one of the most diversified ways of investing ...
  6. Celgene To Buy Receptos For $7.2B; Analysts Mixed

    July 15, 2015
    Celgene Corporation and Receptos announced a definitive agreement in which CELG will acquire Receptos for $232 per share. ...
  7. Celgene's $1 Billion Deal to Fight Cancer

    July 3, 2015
    Wall Street analysts are weighing today on Celgene Corporation after the pharmaceutical giant announced a 10-year broad collaboration ...
  8. Celgene Does Something Surprising With Its Cash

    June 22, 2015
    Source: YCharts. Although shares of biotech blue-chip stock Celgene (NASDAQ: CELG) are relatively unchanged in 2015, shareholders ...
  9. Celgene and Agios Deliver Some Great "Bad" News

    June 17, 2015
    Though the JPMorgan Healthcare Conference and the American Society of Clinical Oncology annual meeting offer, arguably, ...
  10. Could This Tiny Company Threaten Celgene?

    June 12, 2015
    A deal between the small-cap biotech company Sorrento Therapeutics (NASDAQ: SRNE) and a biopharma venture capital company ...
  11. Celgene Takes a Step Back in CAR-T Immunotherapy

    June 8, 2015
    In 2013, Celgene Corp. inked a deal with bluebird bio in which the two companies would leverage their expertise to develop ...
  12. Celgene's 3 Most Important Collaborations

    May 26, 2015
    Biotech blue-chip stock Celgene (NASDAQ: CELG) is arguably the complete package for investors. Celgene has a deep pipeline ...
  13. 5 Things Celgene's Management Wants You to Know

    May 14, 2015
    It has been about two weeks since biotech blue-chip stock Celgene (NASDAQ: CELG) reported its first-quarter earnings results, ...
  14. Is This a Reason to Buy Celgene for the Long Haul?

    May 8, 2015
    Celgene Corporation (NASDAQ: CELG) recently reported intriguing results for luspatercept, a drug it's developing with Acceleron ...
  15. Why Celgene Is Betting on This Tiny Biotech

    April 30, 2015
    Celgene (NASDAQ: CELG) is handing over $100 million in cash and has agreed to pay up to an additional $385 million in milestone ...
  16. Celgene Earnings Preview: What You Need to Know

    April 24, 2015
    It's been quite the ride lately for shareholders in Celgene (NASDAQ: CELG), with the stock returning nearly 200% over the ...
  17. When Will Celgene's Key Patents Expire?

    April 1, 2015
    Drug developers like Celgene (NASDAQ: CELG) are constantly innovating new medicine to offset the risk of sliding sales tied ...
  18. Does Celgene Have Another Blockbuster on the Way?

    March 26, 2015
    Celgene (NASDAQ: CELG) is best known for its cancer medicines, but it could soon be much better known for therapies designed ...
  19. Why These Could Be 2015's 10 Best Biotech Stocks

    March 25, 2015
    A quick look at a 10 biotech companies that are poised to deliver for shareholders in 2015.
  20. 1 Biotech Stock I Wish Would Go On Sale

    March 24, 2015
    Everyone likes a great deal, and there's no biotech stock I'd love to see go on sale more than Celgene (NASDAQ: CELG). Celgene's ...
  21. Why Celgene Won't Pay A Dividend Anytime Soon

    March 12, 2015
    The biotech sector has been virtually unstoppable over the past three years and has widely outperformed the broader market. ...
  22. What Biotech Stock To Buy When The Market Tumbles?

    March 10, 2015
    Since 2013, Biotech's return has tripled the S&P 500, and that may mean that with the market slipping lately, biotech's leading ...
  23. Multiple Myeloma: A Growing Market For Treatment

    February 26, 2015
    American and European regulators have given Celgene Corporation the OK to begin marketing its top-selling myeloma drug Revlimid ...
  24. How On-Balance Volume Reveals Market Players' Strategy

    February 11, 2015
    On-Balance Volume (OBV) reveals the intent of market players, often before price action generates a buy or sell signal.
  25. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  26. Who are Amgen Inc.'s (AMGN) main competitors?

    August 27, 2014
    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.
  27. Four Stocks Setting Up For A Move Lower

    February 12, 2014
    These four stocks have recently broken out of chart patterns, indicting further moves in the breakout direction.
  28. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  29. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  30. Amgen Sweetens The Bid And Secures Onyx

    August 26, 2013
    Amgen finalizes a value-additive deal for Onyx
  31. Pfizer Looking A Little Tired

    July 30, 2013
    Pfizer gets a boost from better margins, but the growth outlook is pretty feeble.
  32. 8 Stages Of New Drug Development

    July 29, 2013
    Understanding biotech data isn't easy. What is a clinical trial, what are the various phases, and why do the results of these ...
  33. Celgene Only Getting Started, But The Street's Already Looking ...

    July 26, 2013
    Biotech valuations are into the nose-bleed zone, but Celgene continues to execute very well.
  34. Amgen Puts Onyx Pharmaceuticals In Play

    July 2, 2013
    An unsolicited $120/share bid has sent Onyx soaring and rival bidders circling.
  35. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  36. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  37. Amgen and Other Healthcare Stocks Making Big Moves on October ...

    October 19, 2012
    The market is having a bad day so far: the Nasdaq has slipped 1.6%; the S&P 500 is trading down 1%; and the Dow is down ...
  38. Playing A Biotech Breakout

    February 15, 2012
    Strong pipelines for the biotech sector as well as a wave of merger activity, have investors flocking to the stocks.
  39. XOMA Rearranges The Deck Chairs One More Time

    September 2, 2011
    XOMA changes management again, but should anybody care?
  40. Are Buybacks A Bad Sign?

    August 24, 2011
    Investors celebrate buybacks, but there is a cost to every decision.
  41. A Dull ASCO And The Usual Sell-Off

    June 7, 2011
    Investors shouldn't be spooked by the normal post-ASCO sell-off
  42. A Deal At Last For Sanofi And Genzyme

    February 18, 2011
    Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
  43. There Is Life After Death, At Least In Biotech

    June 22, 2010
    Clinical failure is not the end of the story for all biotechs. How do some survive while others disappear?
  44. The Best Performing Stocks Of The Decade

    June 9, 2009
    Investors who were able to see past the losses and volatility that some of these companies had in the beginning were amply ...
  45. Biotech ETFs Under The Microscope

    July 24, 2008
    Biotech ETFs have been immune to the falling stock market. We examine three top performing funds to find a surprising long-term ...
Trading Center